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BACKGROUND: Ivacaftor is the first Food and Drug Administration-approved medication to 
treat an underlying genetic defect in patients with cystic fibrosis (CF). With an approximate 
annual cost of $300,000 per patient, ivacaftor may have a profound financial impact on health 
systems, even when utilized by a small population. Clinical data has demonstrated that 
treatment with ivacaftor may reduce pulmonary exacerbations (PE) and associated 
hospitalizations. As a result, patients receiving ivacaftor may need less outpatient care and 
fewer medications to treat CF complications. Evaluating the impact of ivacaftor therapy on 
medication utilization, PEs and hospital/outpatient visits can aid formulary decision makers in its 
effective management. 
 
OBJECTIVES: The primary objective is to examine the effects of ivacaftor on patients’ overall 
medication regimen and associated costs within a Medicaid population. The secondary 
objective is to examine its effect on the rates of PEs and hospital/outpatient visits. 
 
METHODS: Pharmacy and medical claims data for Medicaid members ≥ six years of age was 
collected for six months before and after the first reported pharmacy claim of ivacaftor. Data 
included: total number of unique claims, days supply, dose, and total cost for each medication, 
number of short-term antibiotic and/or steroid courses, outpatient provider visits, 
hospitalizations, ER visits and corresponding diagnosis codes. Diagnosis codes and short-term 
antibiotic and/or steroid courses were reviewed to determine if a PE may have occurred.  
 
RESULTS: Ivacaftor treatment did not decrease the utilization of medications used to treat 
patients with CF and resulted in increased pharmacy expenditures for other medications. 
However, a 65% reduction in PEs as well as a reduction in hospitalizations/ER visits was 
observed in members receiving ivacaftor. 
 
CONCLUSIONS: This study found that while ivacaftor treatment may not decrease total 
medication utilization or associated costs, it may decrease the number of PEs and associated 
hospitalizations in patients with CF. 
                                                          
* Employee of Clinical Pharmacy Services during research design and protocol development 
† Current employee of the University of Massachusetts Medical School Office of Clinical Affairs 
 
